The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human eIF4E that contains serine 209. The sequence is conserved in mouse, rat and rabbit.
Conjugate
Unconjugated
Form
Liquid
Purification
Antigen affinity chromatography
Storage buffer
Dulbecco's PBS, pH 7.3, with 1mg/ml BSA, 50% glycerol
Contains
0.05% sodium azide
Storage Conditions
-20°C
Tested Applications
Dilution *
Flow Cytometry (Flow)
3-5 ug x 10^6 cells
Immunocytochemistry (ICC)
2-3 ug/ml
Immunofluorescence (IF)
2-3 ug/ml
Western Blot (WB)
Assay Dependent
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
All eukaryotic cellular mRNAs are blocked at their 5-prime ends with the 7-methylguanosine cap structure, m7GpppX (where X is any nucleotide). This structure is involved in several cellular processes including enhanced translational efficiency, splicing, mRNA stability, and RNA nuclear export. EIF4E is a eukaryotic translation initiation factor involved in directing ribosomes to the cap structure of mRNAs. It is a 24-kD polypeptide that exists as both a free form and as part of a multiprotein complex termed EIF4F. The EIF4E polypeptide is the rate-limiting component of the eukaryotic translation apparatus and is involved in the mRNA-ribosome binding step of eukaryotic protein synthesis. The other subunits of EIF4F are a 50-kD polypeptide, termed EIF4A (see MIM 601102), that possesses ATPase and RNA helicase activities, and a 220-kD polypeptide, EIF4G. (Rychlik et al., 1987 [PubMed 3469651]).
原厂资料：
注意事项：
For Research Use Only. Not for use in diagnostic procedures.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
